Regulatory of Personalized medicine

The FDA is  already started to take initiatives to integrate personalized medicine into their regulatory policies.They developed a report in October 2013 entitled Paving the Way for Personalized Medicine FDAs role in a New Era of Medical Product Development in which they outlined steps they would have to take to integrate genetic and biomarker information for clinical use and drug development. They determined that they would have to develop specific regulatory science standards, research methods, reference material and other tools in order to incorporate personalized medicine into their current regulatory practices. For example, they are working on a genomic reference library for regulatory agencies to compare and test the validity of different sequencing platforms in an effort to uphold reliability.

  • FDA and Personalized medicine
  • Regulatory aspects of pharmacogenetics
  • FDA and predictive medicine
  • FDA and validation of biomarkers

Related Conference of Regulatory of Personalized medicine

June 21-22, 2017

3rd International Conference on Cytopathology & Histopathology

Philadelphia, Pennsylvania, USA
June 26-27, 2017

8th World Congress on Molecular Pathology

San Diego,California,USA
August 02-03, 2017

13th European Pathology Congress

Milan, Italy
August 23-24, 2017

4th World Congress on Breast Pathology and Cancer Diagnosis

Toronto, Canada [Holiday Inn Toronto International Airport]
Sep 11-12, 2017

World Annual Pathologists Congress

Los Angeles, USA
November 13-14, 2017

14th Asia Pacific Pathology Congress

Osaka, Japan
November 15-16, 2017

2nd International Conference on Digital Pathology

San Antonio, USA

Regulatory of Personalized medicine Conference Speakers

Recommended Sessions

Related Journals

Are you interested in